Technical Analysis The stock is currently trading at $596.99 in pre-market with a +0.75% gain. The RSI(14) at 55.60 indicates neutral momentum, while the MACD shows a slightly positive trend at 1.91. The stock is trading above its 20-day SMA of $580.64, suggesting short-term bullish momentum.

Analyst Consensus Recent analyst ratings strongly favor buying MCK. Citigroup lowered their price target to $677 (still indicating 16.38% upside), while maintaining a Strong Buy rating. Morgan Stanley named MCK a "Top Pick" with a price target of $642, citing drug distributors as "relative safe havens".

Recent Developments

Institutional activity shows mixed sentiment with 615 investors adding positions while 807 decreased their holdings.
The company recently received a $10M government contract for pharmaceutical supplies.
Insider transactions show 4 sales and no purchases in the past 6 months, suggesting some caution from company executives.

Buy Recommendation Based on current technical indicators, strong analyst consensus, and stable business fundamentals, MCK presents a buying opportunity at current levels. The stock's position above key moving averages and multiple price targets indicating 11-16% upside potential support this recommendation.

What is price prediction 2025 for MCK Stock?

Based on the provided data and current market conditions, here's the price prediction for MCK stock in 2025:

McKesson (MCK) is expected to reach $650-675 by the end of 2025, driven by strong institutional support and positive analyst ratings. The current price of $596.99 shows an upward momentum from its recent consolidation phase around $580-590 range.

The prediction is supported by Evercore ISI's price target of $650 and the average analyst consensus of $671, indicating a potential upside of 15% from current levels. The company's robust pharmaceutical distribution business and recent $10M government contract for Tamiflu supplies through August 2025 demonstrate continued business strength.

What is surpport and resistant level for MCK Stock?

The S1 support level for MCK Stock is $576.71 ,The R1 resistant level for MCK Stock is $596.37.

What is the current price of MCK Stock?

As of the end of day on 2025-01-24, the price of MCK Stock was $590.54.

What is the target price of MCK Stock?

The target price for MCK Stock according to analyst rating is 673.73, with the highest price target at 715.00 and the lowest at 630.00. Analysts have a Strong Buy rating on MCK Stock overall.

What is the market cap of Mckesson Corp?

The market cap of MCK is $75.1B.

Is Mckesson Corp (MCK) overvalued?

Based on the latest financial data and analyst ratings, MCK appears fairly valued at current levels. The company's P/E ratio of 25.58x and EV/EBITDA of 13.13x are in line with historical averages. Revenue growth remains strong with Q2 2025 reaching $93.65B, though net income declined to $241M from previous quarters. Recent analyst consensus maintains a Strong Buy rating with an average price target of $671, suggesting about 15% upside potential. Citigroup recently lowered their price target to $677 but maintains a Buy rating, citing that health tech stocks have likely reached a valuation floor. The company's low P/S ratio of 0.20x and stable gross margins around 3.4% indicate efficient operations despite thin industry margins.

What is Mckesson Corp (MCK)'s business?

McKesson Corporation is a provider of diversified healthcare services. The Company is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada.

What is price prediction 2030 for MCK Stock?

Based on analyst projections and market trends, McKesson (MCK) stock is expected to reach approximately $850-900 by 2030, driven by the company's strong market position in healthcare distribution and continued growth in pharmaceutical services. The company's consistent revenue growth, strategic acquisitions, and expansion in healthcare technology solutions support this bullish outlook. Recent analyst consensus maintains a Strong Buy rating with near-term price targets around $671, indicating a steady upward trajectory that could accelerate through 2030 as healthcare demands increase globally.